Open-label single-group study (n=12) giving four psilocybin doses (10 mg then three 25 mg sessions, ≥7 days apart) to healthy volunteers with repeated MRI to map brain and physiological correlates.
The main purpose is to identify reliable brain and bodily reactions arising during the psychedelic experience by repeatedly scanning the same healthy volunteers under psilocybin.
Participants receive four dosing visits: first a 10 mg psilocybin session, then up to three 25 mg sessions at least seven days apart; each dosing visit includes multiple in-scanner runs during which brief valence ratings are collected every 100 seconds.
From screening through final follow-up participants are in the study for approximately 6–12 weeks, with a post-dose phone call the day after each dosing visit to assess wellbeing and experiences.
Healthy volunteers receive up to four doses of psilocybin (10 mg first session, then up to three 25 mg sessions) separated by at least seven days; MRI scans performed during dosing visits.
First session 10 mg; remaining three sessions 25 mg each; sessions ≥7 days apart; scans during dosing.
No exclusion criteria listed.